Intensified chemotherapy regimens resulting in improved survival of children with acute lymphocytic leukemia (ALL) lead to concerns about therapy-induced immune damage reflected by the loss of protection of previous immunizations and the efficacy of (re-)vaccination. The severity of secondary immunodeficiency, however, is not clear and knowledge is based on a limited number of studies. We performed a systematic review on literature concerning vaccination data of children with ALL published since 1980. Eight studies fulfilled the inclusion criteria. Regarding antibody titers after treatment, the number of children who had preserved the defined protection level for antibodies differed widely, ranging from 17 to 98% for diphtheria, 27 to 82% for Bordetella pertussis, 20 to 98% for tetanus, 62 to 100% for poliomyelitis, 35 to 100% for Haemophilus influenzae type B (HiB), 29 to 92% for mumps, 29 to 60% for measles and 72 to 92% for rubella. Most patients however responded to revaccination, demonstrating immunological recovery. Although the designs and results of the included studies varied widely, it can be concluded that cytostatic therapy for ALL in children results in a temporarily reduction of specific antibody levels. Memory is preserved but revaccination may be warranted. This is the first systematic review and the best possible current approximation of chemotherapy-induced immune damage in children after ALL treatment.
Introduction
Tailored and intensified therapy has led to improved survival of children with acute lymphocytic leukemia (ALL) over the last two decades. Currently, the 5-year event-free survival for ALL is improving from about 80% [1] [2] [3] [4] to even 90%. 5 There is concern about therapy-induced immune damage reflected -among others -by loss of protective antibody levels provided by previous immunizations and the reduced efficacy of (re-) immunization. [6] [7] [8] [9] [10] This may reflect loss of immunological memory against infectious diseases in general and is therefore important.
ALL-directed chemotherapy leads to considerable B-cell depletion in the bone marrow and peripheral blood, 11 often accompanied by transient hypogammaglobulinemia. 12 After chemotherapy, B-cells seem to recover within months, [11] [12] [13] whereas the amount of CD4 T-helper cells remains low for longer periods of time, 13, 14 but T-cell memory seems to be spared. 15 Despite the persistence of memory T cells, some loss of immunological memory is observed, as indicated by a suboptimal response to (re-)vaccinations after cessation of chemotherapy in some patients. 16 However, reliable evidence concerning suppression of antibody levels against vaccine-preventable diseases and subdued response to (re-)vaccination in children with ALL is scarce and conflicting. [6] [7] [8] [9] [10] Therefore, it is still not clear if children require revaccination after completion of chemotherapy for ALL. We decided to perform a systematic literature review with respect to vaccination data of children with ALL published since 1980.
Materials and methods

Search strategy
A comprehensive literature search was carried out in PubMed and EMBASE as from January 1980 to January 2006 for articles comprising information on (re-)vaccination in children with ALL (see Appendix A for detailed search strategy). To identify other possible eligible papers reference lists from identified publications were screened, a related article search was carried out, and the ISI Web of Knowledge was used to search for citations. Only peer-reviewed articles published in English were retrieved.
Study selection
Two reviewers independently screened identified titles and abstracts without blinding to authorship or journal. Potentially relevant studies were obtained and the full text examined. Discrepancies between both reviewers were resolved by discussion. The criteria for inclusion in this review were as follows: at least 10 patients per vaccine group, publication after 1980, age below 18 years and vaccination status of study groups presented such that percentage of protected patients could be identified (i.e., data not presented in average antibody titer per patient group).
Data extraction
Data from all included studies were extracted with respect to: type of vaccination, number of patients studied per vaccine, year of publication, study period, protection rate before chemotherapy, time lapse since the end of chemotherapy at the moment of analysis, titer at which patients were considered protected, protection rate after chemotherapy and protection rate after (re-)vaccination (when applicable). In several studies, only a minor part (o10 patients) of the whole patient group was (re-)vaccinated. These small subgroups cannot be regarded as representative for the whole group and were not analyzed in this review (depicted with non-extractable (NE) in the tables).
Statistics
Protection rates and their corresponding 95% confidence intervals (CI) were summarized. The 95% confidence limits were determined according to Wilson's confidence limits for a binomial distribution.
17,18
Results
Study selection
Initially, 195 articles were identified in PubMed. EMBASE revealed two more studies that were not found in PubMed; 27 articles were considered potentially relevant (Figure 1 ). Two additional articles were found by screening the references and citations of these relevant papers. Of these 29 eligible studies, only eight reports met the inclusion criteria. The remaining 21 studies were excluded for the following reasons: only groups less than 10 patients were included (n ¼ 2), 19, 20 no data extraction possible (n ¼ 1), 21 antibodies against vaccine-preventable disease not analyzed (n ¼ 2), 12, 22 results of children could not be distracted from that of adults (n ¼ 1), 23 patients studied were still on chemotherapy (n ¼ 8) [24] [25] [26] [27] [28] [29] [30] [31] and results not stratified for ALL patients only (n ¼ 7). [32] [33] [34] [35] [36] [37] [38] Importantly no randomized controlled trials were available.
Characteristics of included studies per vaccine (Figures 2 and 3 ) Protective antibody levels against diphtheria. According to the predefined serum antibody levels in the studies, protection rates against diphtheria were found above 80% in most studies. In contrast, the studies of Ercan et al. 39 and Ek et al. 16 showed much lower protection rates. In Ercan's study, this may be related to the fact that control subjects and a different patient group at onset of chemotherapy also both failed to reach predefined protective antibody levels. Similar results were observed by Ek et al. 16 who also showed a low protection rate at onset of chemotherapy (Table 1 ). However, in both studies patients showed adequate responses upon (re-)vaccination.
Search strategy run in Pubmed and Embase databases: n=197
Potentially relevant articles identified: n=27
Additional potential relevant articles identified in references: n=1
Additional potential relevant articles identified in ISI Web of Knowledge database for citations: n=1
Total articles for detailed reading: n=29
Articles excluded from analysis -Groups <10 patients: n = 2 -No data extraction possible: n =1 -Specific antibodies not analyzed: n =2 -Children mixed with adults: n =1 -Patients still on chemotherapy:
n =8 -Results not stratified for ALL patient: n =7 -TOTAL: n =21 Articles included in analysis: n=8 
Protective antibody levels against Bordetella pertussis
Three studies showed a wide range in protection rates against B. pertussis, varying between 27 and 82%. This may be partly due to low patient numbers per group and the different definitions for protective antibody levels (see Table 1 ). Again, Ercan et al. 39 also observed low protection rates in control subjects and a different patient group before starting chemotherapy. Importantly, the majority (66%) of patients developed protective antibody titers upon (re-)vaccination.
Protective antibody levels against tetanus
Tetanus is known to be highly immunogenic and overall, protection rates above 69% were observed in most studies. Similar to diphtheria and B. pertussis, the studies of Ercan et al. 39 and Ek et al. 16 showed lower protection rates, but this time Ek et al. found a high protection rate at the onset of chemotherapy, suggesting a real loss of antibody levels after chemotherapy (see Table 1 ). 16, 39 However, again both studies showed a good response to (re-)vaccination.
Protective antibody levels against poliomyelitis
Again, overall protection rates were high (above 70%) in most studies, with the exception of a small study of Smith et al., 40 who showed a lower protection rate. No (re-)vaccination data were reported.
Protective antibody levels against hemophilus influenzae type B Three studies showed a wide range of protection rates varying between 35 and 100%. The study of Brodtman et al. 41 mentioned a low protection rate, but failed to mention their definition of protective antibody level and vaccination status of the patients. In general, two different protective levels are used: 0.15 mg/ml for titer evaluation during follow-up but 4-6 weeks after vaccination with hemophilus influenzae type B (HiB) conjugate vaccine. 1.0 mg/ml better predicts long-term protection. Moreover, HiB conjugate vaccinations started only in the early 1990s of the last century in most countries. Smith et al. 40 did not mention the HiB conjugate vaccination status, whereas Ek et al. 16 reported 50% of their patients to be vaccinated and 50% naturally exposed. Remarkably, (re-)vaccination did not seem to improve the protection rate in these studies in contrast with the previously mentioned vaccines against tetanus, diphtheria and B. pertussis. Abbreviations: N, number of analyzed ALL patients; NA, not applicable; NE, data not extractable; pre-chemo protection, proportion of patients who had a known titer above protection level at the onset of chemotherapy (if this information was available for the whole group, percentage protection is depicted, otherwise it is shown which part of the subgroup was protected); protection, percentage of patients above protective level (this is extracted from the study directly or determined by the number of patients above the given protective titer divided by the total number of patients analyzed); prot. post revacc, percentage of patients above protective level after (re-)vaccination; Prot. titer, titer that was considered protective in the article (in U/ml, unless otherwise indicated); time: months after stop chemotherapy; if a study describes additional groups o10 patients, 'NE' is depicted.
Protective antibody levels against mumps, measles and rubella
The observed protection rates varied widely and ranged from 29 to 92% for mumps, 29 to 60% for measles and 72 to 92% for rubella ( Table 2 ). This may be explained partially by the different definition of protective antibody levels in almost every study. Therefore, no conclusion can be drawn. Only Ercan et al. 39 revaccinated the whole study group, after which 66% and 76% of the patients reached protective antibody titers for mumps and measles, respectively (see Table 2 ). In the other studies, the subgroups for revaccinations were too small for reliable data extraction.
Discussion
This present study is the first systematic review analyzing studies of pediatric ALL patients with respect to their humoral immune status after cessation of chemotherapy. We showed that cytostatic therapy for ALL results in a decrease of protective antibody levels after previous vaccinations according to the national infant vaccination programs in countries. However, most children appear to show protective antibody levels after revaccination, reflecting intact humoral immunity and memory after chemotherapy. The wide ranges in protection rates between the studies can be explained largely by different study design aspects, making it impossible to perform a meta-analysis.
Earlier reviews differ in their opinion about immune damage and recovery from secondary immunodeficiency. [42] [43] [44] As current tailored and intensive combination chemotherapy regimens probably have reached their optimal efficacy, long-term effects like immune damage will stabilize. Therefore, robust studies of sufficient size evaluating secondary immunodeficiency resulting from the current ALL chemotherapy regimens are required for optimal protection of patients against infectious diseases.
6-10 At present, even on the basis of this systematic review, no definitive advice on (re-)vaccination policies can be given owing to heterogeneity between studies and limited sample size. Until further studies clarify this issue, one should consider the degree of vaccination coverage in the community and herd-immunity effects as well as the incidence of vaccinepreventable diseases among ones patient population whether to screen and revaccinate. Unfortunately, there is a clear lack of epidemiologic data concerning the incidence of vaccinepreventable diseases among ALL patients after chemotherapy. Although herd immunity in the western world may reduce the strength of the case for (re-)vaccination, a vaccination still provides the best possible protection. Importantly, increased migration and travel movements might reduce herd immunity. If one decides to perform screening, 3 months after cessation of chemotherapy is an accepted time point, taking into account that B-cell counts have returned to normal at this time point, 11, 12 provided that CD4 T-helper cells are present. Which vaccinepreventable diseases one should screen again depends on the local situation, but it is advisable also to screen for the pneumococcal conjugate vaccine antibody levels as Pneumococci are a frequent cause of both invasive and respiratory tract disease and particularly so after cancer treatment like in ALL patients. 45 Considering the good average memory responses to revaccination, it is not necessary to evaluate the vaccination response, unless the patient is suspected of severe (secondary) immunodeficiency or still has low CD4 T-helper cell counts.
To appreciate the results of this systematic review, some items deserve discussion. First, many studies were excluded from this review as they analyzed patient groups during chemotherapy and/or patient groups with other cancers like other hematological malignancies or solid tumors. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] It was not possible to extract data separately for ALL patients after cessation of chemotherapy from these studies. As a consequence, this review represents homogeneous groups of ALL patients after cessation of chemotherapy.
Second, the differences (or absence) in definition of a protective antibody level add to variability between studies. As shown in Tables 1 and 2 , the authors of the original studies sometimes use protective titer definitions, which are not in SI units and often the defined protective levels may differ significantly, even as much as 10 times, according to the usage of different vaccines and schedules, laboratories for antibody determination and ethnic populations. Also, no age-corrected protective titers were used, as observed in the normal healthy age-matched population.
Third, the reported loss of protective antibody levels is often overestimated by the group of patients who already had no protective antibody level at the onset of chemotherapy, as is common several years after the last (re-)vaccination. This effect can be quite significant (also in healthy children), 35 and was appreciated only in some studies. 16, 46 In addition, response to revaccination should be seen in the context of a memory Table 2 Percentage protection for mumps, measles and rubella (see also response similar to the response in age-matched previously vaccinated healthy children, and referring to the same protective antibody level definition. Only one study provides this information, 47 and some authors refer to literature. Fourth, the time at which an antibody titer was determined and (re-)vaccinations performed varied considerably and was often poorly defined in studies which makes it difficult to draw firm conclusions about immune reconstitution and timing. In addition, antibody levels and revaccination responses are probably dependent on the time between measurement and the number and timing of the regular (booster-)immunizations in children before chemotherapy.
Finally, only studies published since 1980 were included as chemotherapy and vaccination regimens before 1980 were considered not comparable with the current situation. However, HiB conjugate vaccinations were often included in national infant vaccination regimens only in the early 1990s of the last century. The fact that the response upon revaccination with HiB did not seem to improve the protection rate may indicate that the loss of memory against polysaccharide antigens is different compared to protein vaccines. This has to be confirmed, however, in larger studies with documented vaccination status of patients. Furthermore, with respect to B. pertussis different vaccines are used in different countries, with varying immunogenicity. Differences therefore may be partly explained by the different vaccines and schedules used in different countries.
Conclusion
Cytostatic therapy for ALL in children appears to result in a reduction of specific antibody levels. However, most patients showed adequate responses to (re-)vaccination, demonstrating immunocompetence and preservation of memory. The current level of chemotherapy intensity and survival demands a multicenter prospective longitudinal study with a homogenous ALL patient group to obtain more knowledge of the persistence of disturbed memory and restoration of immunity of the current ALL chemotherapy regimens. In the mean time, the question whether to screen and revaccinate patients after chemotherapy for ALL is dependent on the local situation considering the degree of vaccination coverage and incidence of vaccinepreventable diseases.
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